Betta Pharmaceuticals Co.Ltd(300558) 2021 verification of special report on deposit and use of raised funds
About Betta Pharmaceuticals Co.Ltd(300558)
Deposit and use of raised funds in 2021
Assurance report of special report
Xin Hui Shi Bao Zi [2022] No. zf10204 Betta Pharmaceuticals Co.Ltd(300558) all shareholders:
We have accepted the entrustment to carry out reasonable assurance on the attached special report on the deposit and use of raised funds of Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as “the company”) in 2021 (hereinafter referred to as “the special report on raised funds”).
1、 Responsibilities of the board of directors
The responsibility of the board of directors of your company is to comply with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) (CSRC announcement [2022] No. 15) of China Securities Regulatory Commission Prepare a special report on raised funds in accordance with the relevant provisions of the guidelines for self-regulation and supervision of listed companies on the Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem and the guidelines for self-regulation and supervision of listed companies on the gem of the Shenzhen Stock Exchange No. 2 – announcement format. This responsibility includes designing, implementing and maintaining the internal control related to the preparation of the special report on raised funds to ensure that the special report on raised funds is true, accurate and complete without false records, misleading statements or major omissions.
2、 Responsibilities of Certified Public Accountants
Our responsibility is to publish the assurance conclusion of the special report on raised funds on the basis of the implementation of the assurance work.
3、 Job overview
We have carried out the assurance business in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information. The standards require us to abide by the code of professional ethics, plan and implement the assurance work, so as to determine whether the special report on raised funds is in accordance with the regulatory guidelines for listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies (revised in 2022) (CSRC announcement [2022] No. 15) of China Securities Regulatory Commission in all major aspects The relevant provisions of the self regulatory guidelines for listed companies on the Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem and the self regulatory guidelines for listed companies on the gem of the Shenzhen Stock Exchange No. 2 – announcement format are prepared to truthfully reflect the deposit and use of the raised funds of your company in 2021 in all major aspects and obtain reasonable assurance. In the process of carrying out the assurance work, we have implemented the procedures we consider necessary, including inquiry, inspection of accounting records and so on. We believe that our assurance work provides a reasonable basis for issuing assurance conclusions.
4、 Assurance conclusion
We believe that your company’s special report on the deposit and use of raised funds in 2021 is in accordance with the regulatory guidelines for listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) (CSRC announcement [2022] No. 15) of China Securities Regulatory Commission in all major aspects The preparation of the relevant provisions of the self regulatory guidelines for listed companies on the Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem and the self regulatory guidelines for listed companies on the gem of the Shenzhen Stock Exchange No. 2 – announcement format truthfully reflects the deposit and use of the raised funds of your company in 2021.
5、 Report usage restrictions
This report is only for the purpose of disclosing the 2021 annual report of your company, and shall not be used for any other purpose.
Chinese Certified Public Accountants of Lixin certified public accountants:
(special general partnership)
Chinese certified public accountant:
Shanghai, China April 1, 2002
Special report on the deposit and use of raised funds in 2021
According to the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) (CSRC announcement [2022] No. 15) The relevant provisions of Shenzhen Stock Exchange self regulatory guidelines for listed companies No. 2 – standardized operation of GEM listed companies and Shenzhen Stock Exchange self regulatory guidelines for GEM listed companies No. 2 – announcement format, GEM listed companies business handling guidelines No. 6 – information disclosure announcement format (revised in 2021), The company made the following special report on the deposit and use of raised funds in 2021: I. Basic information of raised funds (I) actual amount of raised funds and funds in place
1. Availability of funds raised by initial public offering
Approved by the China Securities Regulatory Commission in the reply on Approving the initial public offering of shares by Betta Pharmaceuticals Co.Ltd(300558) Co., Ltd. (zjxk [2016] No. 2350), it is approved to publicly issue 41 million RMB ordinary shares (A shares), with a par value of 1 yuan per share and an issue price of 17.57 yuan / share, and the total amount of raised funds is 72037000000 yuan, After deducting the underwriter’s issuance fee of RMB 4800000000, the raised funds of RMB 67237000000 have been fully transferred to the bank account of the company. After deducting the advance recommendation fee of RMB 200000000 and other listing expenses of RMB 1302000000 in previous years, the net amount of raised funds is RMB 65735000000. The above funds have been fully paid on November 2, 2016. The availability of raised funds has been verified by Lixin Certified Public Accountants (special general partnership) and issued the capital verification report (xksbz [2016] No. 610851). The company has adopted a special account storage system for the raised funds.
2. Availability of funds raised by issuing shares to specific objects
The registration was approved by the China Securities Regulatory Commission in the reply on Approving the registration of Betta Pharmaceuticals Co.Ltd(300558) Co., Ltd. to issue shares to specific objects (zjxk [2020] No. 2213), and Betta Pharmaceuticals Co.Ltd(300558) issued 10138621 shares to specific objects, with an issue price of 98.83 yuan per share and a total raised capital of 100199991343 yuan, The balance of RMB 99699991343 after deducting the recommendation and underwriting expenses of RMB 500000000 (including tax) has been transferred to the bank account of the company.
The total amount of funds raised by the company this time is RMB 100199991343. After deducting the issuance expenses of RMB 659453873 (including underwriting and recommendation expenses of RMB 471698113, other accountant expenses of RMB 75471698 and lawyer expenses of RMB 112284062 related to this issuance), the actual net amount of funds raised is RMB 99540537470. The above funds have been verified by Lixin Certified Public Accountants (special general partnership) and issued a capital verification report (xksbz [2020] No. zf10986). The company has adopted a special account storage system for the raised funds.
（2） Utilization and balance of raised funds in 2021
As of December 31, 2021, the amount used by the company is:
1. Use of funds raised by initial public offering
Detailed amount (yuan)
On November 2, 2016, the balance of the special account for raised funds was 65735000000 plus: the amount of accumulated interest income minus handling charges was 65428241 plus: the amount of accumulated income of financial products raised funds was 386069865 minus: the amount directly invested in projects raised 66186498106 of which: the amount of advance investment of raised funds replacement (excluding the issuance cost of advance investment of replacement) 4 Shandong Hi-Speed Company Limited(600350) 1039 permanent supplementary working capital amount
On December 31, 2021, the balance of the special account for raised funds was 0.00
Note: the funds raised from the initial public offering of shares have been used up on June 30, 2019, and the corresponding special account for raised funds has been cancelled in 2019.
2. Use of funds raised by issuing shares to specific objects
Detailed amount (yuan)
On November 24, 2020, the balance of the special account for raised funds was 99699991343 plus: the amount of accumulated interest income deducting handling charges was 814967376 plus: the amount of accumulated income of financial products raised funds was 678850929 minus: the amount directly invested in projects raised 27255435140 of which: the amount invested in advance in the replacement of raised funds (excluding the issuance expenses invested in advance in the replacement) 17548012225 minus: the balance of temporarily idle raised funds to purchase financial products is 20000000000 minus: the amount of permanent supplementary working capital is 25340537470 minus: the balance of special account for raised funds paid for issuance expenses is 159453873 as of December 31, 2021 284383,831.65
Note: as of December 31, 2021, the company has invested 27255435140 yuan of raised funds in the investment projects of raised funds, 25340537470 yuan of permanent supplementary working capital, 9529599892 yuan of direct investment projects of raised funds in this year, and 17548012225 yuan of replacement investment projects of raised funds in advance in this year, The amount of permanent supplementary working capital in this year is 33266038 yuan. On December 31, 2021, the actual balance in the special account for raising funds by issuing shares to specific objects was 284383165 yuan. 2、 Deposit and management of raised funds (I) management of raised funds
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the notice on further regulating the use of raised funds by listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the guidelines for the standardized operation of GEM listed companies of Shenzhen Stock Exchange and other laws, regulations and normative documents of China Securities Regulatory Commission, Formulated the management system of Betta Pharmaceuticals Co.Ltd(300558) raised funds (hereinafter referred to as the “management system”)
Management system), which has made specific and clear provisions on the storage, application, change and supervision of raised funds. The company manages the raised funds in strict accordance with the provisions of the management system, and there is no violation of the provisions of the management system in the storage, application, change and supervision of the raised funds.
Among the funds raised from the initial public offering, the company worked with the sponsor China International Finance Corporation Limited (hereinafter referred to as ” China International Capital Corporation Limited(601995) “) and China Construction Bank Corporation(601939) Hangzhou Yuhang sub branch, Bank Of Hangzhou Co.Ltd(600926) technology sub branch and China Citic Bank Corporation Limited(601998) Hangzhou Yuquan sub branch on November 22, 2016
